Structure-to-Efficacy Relationship of HPMA-Based Nanomedicines: The Tumor Spheroid Penetration Study.
HPMA polymers
cytotoxicity
penetration
pirarubicin
tumor spheroids
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Dec 2020
20 Dec 2020
Historique:
received:
01
12
2020
revised:
17
12
2020
accepted:
17
12
2020
entrez:
9
1
2021
pubmed:
10
1
2021
medline:
10
1
2021
Statut:
epublish
Résumé
Nanomedicines are a novel class of therapeutics that benefit from the nano dimensions of the drug carrier. These nanosystems are highly advantageous mainly within cancer treatment due to their enhanced tumor accumulation. Monolayer tumor cells frequently used in routine preclinical assessment of nanotherapeutics do not have a spatial structural architecture that allows the investigation of the penetration of nanomedicines to predict their behavior in real tumor tissue. Therefore, tumor spheroids from colon carcinoma C26 cells and glioblastoma U87-MG cells were used as 3D in vitro models to analyze the effect of the inner structure, hydrodynamic size, dispersity, and biodegradability of
Identifiants
pubmed: 33419291
pii: pharmaceutics12121242
doi: 10.3390/pharmaceutics12121242
pmc: PMC7766879
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LTAUSA18083
Organisme : Grantová Agentura České Republiky
ID : 19-01417S
Références
Biology (Basel). 2016 Dec 06;5(4):
pubmed: 27929413
Int J Pharm. 2018 Jan 30;536(1):108-115
pubmed: 29133205
Mol Pharm. 2019 Aug 5;16(8):3452-3459
pubmed: 31294568
J Am Assoc Lab Anim Sci. 2015 Mar;54(2):120-32
pubmed: 25836957
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Nanoscale. 2018 Mar 29;10(13):6194-6204
pubmed: 29560983
Bioconjug Chem. 2019 May 15;30(5):1371-1384
pubmed: 30946570
Anticancer Res. 2017 Nov;37(11):6063-6069
pubmed: 29061786
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Int J Mol Sci. 2013 Nov 26;14(12):23315-29
pubmed: 24287908
Int J Nanomedicine. 2007;2(2):265-74
pubmed: 17722554
J Control Release. 2014 Jan 28;174:81-7
pubmed: 24269967
Acta Biomater. 2020 Apr 1;106:256-266
pubmed: 32058082
Biomaterials. 2020 Mar;235:119728
pubmed: 32044514
J Drug Target. 2011 Dec;19(10):874-89
pubmed: 21978286
Macromol Biosci. 2018 Jan;18(1):
pubmed: 28805040
Biomacromolecules. 2018 Oct 8;19(10):4003-4013
pubmed: 30180562
J Control Release. 2020 Dec 10;328:160-170
pubmed: 32860930
Eur J Pharm Sci. 2010 Nov 20;41(3-4):473-82
pubmed: 20696244
Curr Opin Colloid Interface Sci. 2017 Sep;31:30-42
pubmed: 29276426
J Control Release. 2016 Feb 10;223:1-10
pubmed: 26708020
Cancer Sci. 2015 Mar;106(3):270-8
pubmed: 25529761
Biology (Basel). 2014 May 30;3(2):345-67
pubmed: 24887773
Nanomedicine. 2019 Oct;21:102059
pubmed: 31310808
Physiol Res. 2016 Oct 20;65(Suppl 2):S179-S190
pubmed: 27762584
Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8177-81
pubmed: 27382181
Pharmaceutics. 2020 Jan 28;12(2):
pubmed: 32013056
Eur J Pharm Biopharm. 2015 Feb;90:90-6
pubmed: 25460144
Mol Pharm. 2013 Oct 7;10(10):3832-41
pubmed: 23947777
Jpn J Cancer Res. 1999 Jul;90(7):775-80
pubmed: 10470291
J Drug Target. 2004;12(8):477-89
pubmed: 15621674